Business
Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced the upcoming presentation of three abstracts at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, taking place May 30-June 2, 2026, in Los Angeles, California.
About this update from Actinium Pharmaceuticals, Inc. (delaware)
[{"type":"text","content":"– ATNM-400 in NSCLC: New data demonstrates ATNM-400's potential in KRAS-mutatedmodels supporting its development as a mutation-agnostic therapy in settings whereresistance to EGFR- and KRAS-targeted agents remains a major clinical challenge","length":246,"tagName":"p","attribs":{}},{"type":"text","content":"– ATNM-400 in prostate cancer: New data further supports ATNM-400 as a potentialtreatment option across the spectrum of PSMA-high, PSMA-low, and PSMA-negativedisease, addressing a key limitation of PSMA-targeted therapies","length":223,"tagName":"p","attribs":{}},{"type":"text","content":"– Radioconjugation platform: New data demonstrates that optimizing chelator-to-antibody ratio(CAR) improves tumor targeting, internalization, and pharmacokinetics of 225Ac-labeledantibodies, directly supporting ATNM-400 development and reinforcing a proprietaryradiochemistry capability that underpins Actinium's broader pipeline","length":336,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, May 6, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced the upcoming presentation of three abstracts at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, taking place May 30-June 2, 2026, in Los Angeles, California.","length":388,"tagName":"p"},{"type":"image","alt":"FINAL LOGO ACTINIUM PHARMA - 1 (PRNewsfoto/Actinium Pharmaceuticals, Inc.)","displaySize":"","headline":null,"caption":"FINAL LOGO ACTINIUM PHARMA - 1 (PRNewsfoto/Actinium Pharmaceuticals, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/eb2937f11974a18d93e636c38ac22747"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2ly3VsOp2jS2V1gWo4DjwQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNQ--/https://media.zenfs.com/en/prnewswire.com/eb2937f11974a18d93e636c38ac22747","width":400,"height":400},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/T6u76zxB4MoAFJUtuHsCVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTY0MA--/https://media.zenfs.com/en/prnewswire.com/eb2937f11974a18d93e636c38ac22747","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/730678/Actinium_Pharmaceuticals_Logo.html","hrefExternal":true,"rel":"no...